Curated News
By: NewsRamp Editorial Staff
October 29, 2026
Regentis Biomaterials Advances GelrinC Cartilage Repair Technology
TLDR
- Regentis Biomaterials targets a 470,000-case U.S. cartilage repair market with GelrinC, which showed 100% greater pain improvement than microfracture.
- GelrinC is a cell-free hydrogel implant that resorbs over six to nine months as new cartilage tissue fills the treated knee area.
- Regentis Biomaterials advances GelrinC to deliver lasting pain relief and mobility improvements for patients with knee cartilage damage.
- Regentis Biomaterials reported a mean MOCART score of 88.8 out of 100 at 24 months for GelrinC cartilage repair.
Impact - Why it Matters
This news matters because Regentis Biomaterials is developing a potentially transformative solution for knee cartilage repair, a condition affecting hundreds of thousands of Americans annually with limited off-the-shelf treatment options. GelrinC’s promising clinical results, including significant pain reduction and high-quality cartilage repair scores, could offer patients a durable, long-lasting alternative to traditional microfracture surgery. As the company advances its Phase III trial and prepares for FDA approval, successful commercialization could reshape orthopedic medicine by providing a readily available, regenerative treatment that improves mobility and quality of life for patients worldwide.
Summary
Regentis Biomaterials (NYSE American: RGNT) is making strides in regenerative cartilage repair with its lead product GelrinC, a cell-free, off-the-shelf degradable hydrogel implant designed to regenerate knee cartilage. In a recent article, the company highlighted its technology, which gradually resorbs over six to nine months as new tissue fills the treated area. Regentis reports that its Pilot/Phase II study demonstrated 100% greater pain improvement compared with traditional microfracture treatment, and 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure of cartilage repair quality.
GelrinC has received a CE mark in Europe, providing a commercialization pathway in that market, while Regentis advances its pivotal Phase III clinical study in the United States and prepares for the FDA’s Premarket Approval process. The company is also working to complete enrollment in its U.S. study and expand commercialization efforts, focusing on developing cartilage repair solutions intended to deliver lasting improvements in pain and mobility. Regentis aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. To view the full article, visit https://ibn.fm/cTSlo.
The content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT. The dissemination is powered by IBN, a dynamic brand portfolio that includes MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance visibility of private and public companies within the investment community.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials Advances GelrinC Cartilage Repair Technology
